ALS Community Urges FDA to Act on Treatment Access, Research Support
People living with amyotrophic lateral sclerosis (ALS) recently shared their views on the importance of new therapies and incremental…
Articles by Marta Figueiredo, PhD
Grant Backs CRISPR Therapy Research for Familial ALS
Researchers at the University of Texas at Dallas (UT Dallas) have received an award from the U.S. Army Medical Research…
Cytokinetics Renews Partnership With The ALS Association
Cytokinetics has reaffirmed its partnership with The ALS Association in the fight against amyotrophic lateral sclerosis (ALS) by…
Approved Diagnostic Molecule in Preclinical Studies to Evaluate Potential in ALS
Researchers at the University of Queensland in Australia have begun preclinical studies of macimorelin, Aeterna Zentaris’ approved oral…
CNM-Au8 May Be Responsible for Slower ALS Progression Seen in Phase 2 Trial
Note: This story was updated Sept. 21, 2021, to note that 18% of patients, not 80%, experienced increases in…
SOL-257 Gene Therapy Targeting TDP-43 Shows Promise in Mice
SOL-257, an experimental gene therapy developed by SOLA Biosciences, delayed disease progression and prolonged the lifespan of a…
Netherlands Researcher Wins 2021 Sheila Essey Award for Genetics Work
Jan Veldink, a neurologist from the Netherlands whose work in the genetics of amyotrophic lateral sclerosis (ALS) has led…
Boosting Cell Stress Response May Be Promising Therapy Approach
A combination of guanabenz — an approved therapy for high blood pressure — plus riluzole slowed disease progression in adults…
Biogen Agrees to Tofersen Access in July for Rapidly Advancing ALS
People with very rapidly progressing familial amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene may gain early access to…
#AANAM – Progression May Be Evident in About 1.5 Years of Radicava Start
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22.